Table 1.
Demographics and clinical features of the study cohort (N=233)
| Age, years [Median (range)] | 69.1 | (42.6–92.6) |
| FIGO Stage | ||
| IIIA | 1 | (0.4) |
| IIIB | 3 | (1.3) |
| IIIC | 67 | (28.8) |
| IV | 161 | (69.1) |
| Histology | ||
| High Grade Serous Carcinoma | 194 | (83.3) |
| Mullerian Carcinoma | 29 | (12.4) |
| Carcinosarcoma | 4 | (1.7) |
| Clear Cell Carcinoma | 2 | (0.9) |
| Low grade serous | 2 | (0.9) |
| Other | 2 | (0.9) |
| Genetic testing | ||
| Not Tested | 50 | (21.5) |
| Negative | 144 | (61.8) |
| Positive | 33 | (14.2) |
| BRCA1 | 20 | (8.6) |
| BRCA2 | 13 | (5.6) |
| VUS | 6 | (2.6) |
| NACT Indications | ||
| Unresectable disease | 200 | (85.8) |
| Comorbidity | 30 | (12.9) |
| Other | 3 | (1.3) |
Data are expressed as n (%) unless otherwise specified
NACT neo-adjuvant chemotherapy; VUS variant of uncertain significance; FIGO The International Federation of Gynecology and Obstetrics; BRCA Breast Cancer gene